Through collaborative hit-to-lead projects, identify new leads with activity in animal models of disease and the potential for further optimization
current phase of drug development
updated 1 Jun 2021
Hit-to-lead is a dynamic phase in the drug discovery process in which small molecule hits from high throughput screens are evaluated and undergo optimization to identify promising lead compounds.
The process of hit-to-lead optimization is ongoing, with multiple series being progressed based on outputs of the screening programme. A variety of hit-to-lead mechanisms and exploration strategies are being used to progress towards in vivo proof-of-concept studies in pre-clinical efficacy models of leishmaniasis.
The NTD Drug Discovery Booster is a related project conducting early-stage drug discovery to identify new treatments for leishmaniasis and Chagas disease.
Get our latest news, personal stories, research articles, and job opportunities.